← Eichor
Condition: Urothelial Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Urothelial Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Phase N/A · 1 location(s) · Lahey Clinic · NCT00872495Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Uppe
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05775471Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Phase N/A · 1 location(s) · OHSU Knight Cancer Institute · NCT07726602Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860Chemoablation for Low-Grade Bladder Cancer
Phase 2 · 1 location(s) · Ekaterina Laukhtina · NCT07019220A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Phase 3 · 62 location(s) · UroGen Pharma Ltd. · NCT06774131Liquid Biospy for Urinary Cancers
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06116396Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
Phase 2/Phase 3 · 4 location(s) · University of British Columbia · NCT06124976Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT04892849A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06982794Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients W
NA · 20 location(s) · Pacific Edge Limited · NCT06394869Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
Phase 2 · 4 location(s) · Erasmus Medical Center · NCT05600127Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
Phase N/A · 2 location(s) · Peking University First Hospital · NCT06598761Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07390617This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05394337Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Phase 2 · 9 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT04617756Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
NA · 2 location(s) · Johns Hopkins University · NCT07225205A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)
Phase N/A · 1 location(s) · Chinese University of Hong Kong · NCT05438537Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary
Phase 2/Phase 3 · 258 location(s) · National Cancer Institute (NCI) · NCT04628767Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Registry Platform Urologic Cancer
Phase N/A · 1 location(s) · iOMEDICO AG · NCT033742679MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT07314723Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 · 6 location(s) · Deciphera Pharmaceuticals, LLC · NCT06966024Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4 · 13 location(s) · Astellas Pharma Global Development, Inc. · NCT06862219
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.